The FDA on August 5, 2022, approved ENHERTU® for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting, or developed disease recurrence during or within six months of completing adjuvant chemotherapy. ENHERTU® is a product of Daiichi Sankyo, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
